Show simple item record

dc.contributor.advisorBolaños, Marcos
dc.contributor.authorRobledo De La Hoz, Tito Isaac
dc.contributor.authorParodi Saltaren, Carlos José
dc.coverage.spatialBarranquillaspa
dc.date.accessioned2020-01-17T19:03:55Z
dc.date.available2020-01-17T19:03:55Z
dc.date.created2018
dc.identifier.urihttps://hdl.handle.net/10901/17742
dc.description.abstractEl reconocimiento de factores de riesgo asociados al ingreso a Unidad de Cuidados Intensivos Pediátricos (UCIP) en pacientes con neutropenia febril, es de gran utilidad para el pediatra y la comunidad médica en general, ya que esta orientara en la estratificación de riesgo de estos pacientes y podrá mejorar conductas terapéuticas y diagnósticas, en esta población de frecuente consulta. Se presenta un estudio analítico retrospectivo tipo casos y controles, diseñado con el objetivo de determinar los factores de riesgo asociados a ingreso a Unidad de Cuidados Intensivos Pediátricos (UCIP) en pacientes con Neutropenia Febril, en la Clínica Prevenir de la ciudad de Barranquilla, periodo enero a junio de 2018. Se concluye que los factores de riesgo asociados a requerimiento de ingreso a UCIP en esta serie, son tiempo ≤ 4 días desde último ciclo de quimioterapia con riesgo 16.1 veces mayor y recuento de plaquetas < 50000 plaquetas/µL con riesgo 12.3 veces mayor.spa
dc.description.abstractThe recognition of risk factors associated with admission to the Pediatric Intensive Care Unit (PICU) in patients with febrile neutropenia, is very useful for the pediatrician and the medical community in general, since it will guide the risk stratification of these patients and may improve therapeutic and diagnostic behaviors in this population of frequent consultation. A retrospective analytical study of cases and controls is presented, designed with the objective of determining the risk factors associated with admission to the Pediatric Intensive Care Unit (PICU) in patients with Febrile Neutropenia, in the Prevent Clinic of the city of Barranquilla, period January to June 2018. It is concluded that the risk factors associated with the requirement of admission to PICU in this series, are time ≤ 4 days since the last chemotherapy cycle with 16.1 times greater risk and platelet count <50,000 platelets / µL with risk 12.3 times higher.Eng
dc.formatPDFspa
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleFactores de riesgo asociados a ingreso a UCIP en pacientes con neutropenia febril ClÍnica Prevenir Barranquilla enero – junio de 2018spa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.subject.subjectenglishNeutropeniaspa
dc.subject.subjectenglishHealth institutionsspa
dc.subject.subjectenglishHospitals - Risk Managementspa
dc.subject.subjectenglishPediatric intensive carespa
dc.subject.lembNeutropenia maligna -- Investigaciones -- Barranquilla (Colombia)spa
dc.subject.lembCuidados intensivos pediátricosspa
dc.subject.lembHospitales – Administración de riesgosspa
dc.type.localTesis de Especializaciónspa
dc.relation.referencesPérez J. Neutropenia febril en pediatría. CCAP Precob SCP. 2011. (12)1:33-45.spa
dc.relation.referencesLane S, Kohler J. The management of febrile neutropenia. Current Paediatrics 2005; 15: 400-405spa
dc.relation.referencesPhillips RS, Wade R, Lehrnbecher T, Stewart L a, Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC medicine. BioMed Central Ltd; 2012 Jan;10(1):6.spa
dc.relation.referencesNavarrro J, Sanchez W. Factores de riesgo de ingreso a UCI en pacientes con neutropenia febril, Clínica prevenir Barranquilla y Fundación Hospital Universitario Metropolitano, enero – octubre de 2011. Tesis de grado UniMetro. 2012.spa
dc.relation.referencesSantolaya ME, Rabagliati R, Bidart T, Paya E, Guzman AM, Morales R et al. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia]. Rev Chilena Infectol 2005;22 Suppl 2:S79-113spa
dc.relation.referencesFreifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011 February 15;52(4):e56-e93spa
dc.relation.referencesJaramillo C, Valencia I, Aristizábal M. Neutropenia febril en pacientes pediátricos: un enfoque diagnóstico y terapéutico Iatreia, 2009; 22(3): 235-245spa
dc.relation.referencesLai HP, Hsueh PR, Chen YC, Lee PI, Lu CY, Lu MY, et al. Bacteremia in hematological and oncological children with febrile neutropenia: experience in a tertiary medical center in Taiwan. J Microbiol Immunol Infect 2003; 36: 197-202.spa
dc.relation.referencesHughes WT, Armstron D, Bodey GP, Bow EJ, Brown EA, Calandra T, et al. 2002 Guidelines for the use for antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-51.spa
dc.relation.referencesAmman RA, Aebi C, Hirt A. Fever in neutropenia in children and adolescents: Evolution over time of main characteristics in a single center, 1993-2001. Support Care Cancer. 2004. (12):826-32spa
dc.relation.referencesLópez P, López E. Neutropenia febril en pediatría. Infectio 2008;12(1):64-71.spa
dc.relation.referencesRincón C. Caracterización de episodios de neutropenia febril en niños con cáncer en la Fundación Hospital de la Misericordia. Uni Nacional. 2013; 1-71spa
dc.relation.referencesComité Nacional de Infectología Pediátrica. [Consensus on management of children with cancer, neutropenia and fever: Update 2008-2009]. Archivos argentinos de pediatría. 2010;108(2):e47–70.spa
dc.relation.referencesDe Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21 (5):v252–6.spa
dc.relation.referencesGuzmán P, Ruiz J. Neutropenia febril en Pediatría: ¿qué punto de corte usar?. Pediatría. 2012; 45(3):195-202spa
dc.relation.referencesLucas KG, Brown AE, Armstrong D, Chapman D, Heller G. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer. 1996;77(4):791-8.spa
dc.relation.referencesBate J, Gibson F, Johnson E, Selwood K, Skinner R, Chisholm J, et al. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151). Archives of disease in childhood Education and practice edition. 2013;98(2):73-5spa
dc.relation.referencesDepartamento de estadistica, Clínica Prevenir Bonadonna, 2017spa
dc.relation.referencesHughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51spa
dc.relation.referencesPaganini H, Santolaya E, Álvarez M, Araña M, Arteaga R, Bonilla A et al. Diagnóstico y tratamiento de la neutropenia febril en niños con cáncer: Consenso de la Sociedad Latinoamericana de Infectología Pediátrica. Rev. chil. infectol. 2011; 28(1):10-38.spa
dc.relation.referencesRamphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities change of the currently isolated pathogens. Clin Infect Dis 2004; 39: S25-S31.spa
dc.relation.referencesMarchetti O, Calandra T. Infections in neutropenic cancer patients. Lancet 2002; 359: 723-5spa
dc.relation.referencesYadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003; 37: 1144-5spa
dc.relation.referencesLaurichesse H, Romaszko JP, Nguyen LT, Souweine B, Poirier V, Guólon D. Clinical characteristics and outcome of patients with invasive pneumococcal disease Puy de Dóme France1994-1998. Eur J Clin Microbiol Infect Dis 2001; 20: 299-308spa
dc.relation.referencesZaoutis TE, Roilides E, Chiou CC, Buchanan WL, Knudsen TA, Sarkisova TA. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007; 26: 723-7spa
dc.relation.referencesVelasco E, Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis 2008; 27: 1071-8spa
dc.relation.referencesRamphal R, Grant RM, Dzolganovski B, Constantin J, Tellier R, Allen U. Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study. Pediatr Infect Dis J 2007; 26: 700-4spa
dc.relation.referencesTager FM, Zolezzi RP, Folatre BI, Navarrete CM, Rojas PJ. Respiratory virus infections in children with acute lymphoblastic leukemia and febrile neutropenia: a prospective study. Rev Chil Infectol 2006; 23: 118-23spa
dc.relation.referencesRackoff W, Gonin R, Robinson C, Kreissman SG, Breitfeld PB. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996; 14: 919-24spa
dc.relation.referencesKlaasen RJ, Goodman TR, Pham B, Doyle JJ. Low risk prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18: 1012-9spa
dc.relation.referencesSantolaya ME, Alvarez A, Becker A, Cofré J, Enríquez N, O'Ryan M. Prospective, multicenter evaluation of risk factors associated with invasive bacterial 36 infection in children with cáncer, neutropenia and fever. J Clin Oncol 2001; 19: 3415-21spa
dc.relation.referencesSantolaya ME, Alvarez A, Avilés CL, Becker A, Cofré J, Enríquez N. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever and neutropenia. Clin Infect Dis 2002; 35: 67883spa
dc.relation.referencesSantolaya ME, Alvarez AM, Avilés CL, Becker A, King A, Mosso C. Predictors of severe sepsis not clinically apparent during the first twenty four hours of hospitalization in children with cancer neutropenia and fever: a prospective multicenter trial. Pediatr Infect Dis J 2008; 27: 538-43spa
dc.relation.referencesBasu SK, Fernández ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005; 23: 7958-66spa
dc.relation.referencesPaganini H, Aguirre C, Puppa G, Garbini C, Javier R G, Ensinck G. A prospective, multicentric screening system to predict mortality in febrile neutropenic children with cancer. Cancer 2007; 109: 2572-9spa
dc.relation.referencesSantolaya ME, Alvarez A, Becker A, Avilés CL, Becker A, Mosso C. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenia episode. Pediatr Infect Dis J 2007; 26: 794-8spa
dc.relation.referencesRivas R. Consenso mexicano para el abordaje diagnóstico y terapéutico del paciente con neutropenia febril. Rev Hematol Mex 2014;15 (2):207-268spa
dc.relation.referencesSuárez D, Álvarez M, Gómez J, Carrasco M, Burbano D. Caracterización clínica y de laboratorio de pacientes con neutropenia febril en un hospital pediátrico en Pasto-Colombia. Pediatr. 2016;49(2):48–53spa
dc.relation.referencesVizcaíno H. Caracterización clínica y epidemiológica de los pacientes pediátricos oncológicos con neutropenia febril. Uni de Cartagena, 2014:1-24spa
dc.identifier.instnameinstname:Universidad Librespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad Librespa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.subject.proposalNeutropeniaspa
dc.subject.proposalInstituciones de saludspa
dc.subject.proposalCuidados intensivos pediátricosspa
dc.subject.proposalHospitales -- Administración de riesgosspa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/2.5/co/